CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

20 Jan 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · SLE - Systemic Lupus Erythematosus · Phase 1 · Enrollment 12 · Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Cardiology on 20 Jan 2026. The item focuses on CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases. Open the detail page to review the full original feed content.